BiOptic Inc.
BiOptic Inc., a biotechnology instrumentation company, develops scientific products for research and clinical applications. It offers instruments, such as bio-fragment analyzers and PCR thermocyclers; consumables, including DNA, RNA, and protein cartridges, as well as quantification kits; premix and polymerase PCR reagents; and veterinary, human, and food related testing kits. BiOptic Inc.was fou… Read more
BiOptic Inc. (6850) - Total Liabilities
Latest total liabilities as of June 2025: NT$131.64 Million TWD
Based on the latest financial reports, BiOptic Inc. (6850) has total liabilities worth NT$131.64 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BiOptic Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how BiOptic Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BiOptic Inc. Competitors by Total Liabilities
The table below lists competitors of BiOptic Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
King House CO., Ltd.
TWO:4419
|
Taiwan | NT$2.26 Billion |
|
BIOTIME
BE:BT3
|
Germany | €31.80 Million |
|
United Bank Ltd
KAR:UBL
|
Pakistan | PKRs7.52 Trillion |
|
ScripsAmerica Inc
PINK:SCRCQ
|
USA | $9.66 Million |
|
Waste Plastic Upcycling AS
OL:WPU
|
Norway | Nkr170.78 Million |
|
Gemfields Plc
LSE:GEM
|
UK | GBX206.14 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down BiOptic Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BiOptic Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BiOptic Inc. (2020–2024)
The table below shows the annual total liabilities of BiOptic Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$134.66 Million | -21.05% |
| 2023-12-31 | NT$170.56 Million | +81.29% |
| 2022-12-31 | NT$94.08 Million | +110.53% |
| 2021-12-31 | NT$44.69 Million | -59.25% |
| 2020-12-31 | NT$109.66 Million | -- |